Skip to main content

Drug Interactions between landiolol and Tikosyn

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dofetilide landiolol

Applies to: Tikosyn (dofetilide) and landiolol

GENERALLY AVOID: Concomitant use of landiolol with negative inotropes, medications that slow heart rate or cardiac conduction should be done with caution. Coadministration may result in additive suppression of cardiac function, atrioventricular (AV) conduction abnormalities, prolonged PR interval, and potentially additive heart-rate and blood pressure lowering effects. Landiolol alone is associated with increased risk of bradycardia and heart block, and therefore coadministration with these agents may potentiate these effects.

MANAGEMENT: If coadministration is clinically necessary, careful titration of the landiolol infusion and close hemodynamic monitoring is advised. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

References (2)
  1. (2024) "Product Information. Sibboran (landiolol)." Trimedic Therapeutics Inc.
  2. (2024) "Product Information. Rapiblyk (landiolol)." AOP Orphan Pharmaceuticals GmbH

Drug and food interactions

Minor

dofetilide food

Applies to: Tikosyn (dofetilide)

In vitro data suggest that grapefruit juice may inhibit the CYP450 3A4 first-pass metabolism of dofetilide. Decreased first-pass metabolism may increase dofetilide concentrations and increase the risk of QT interval prolongation and arrhythmias. The clinical significance is unknown, since dofetilide has a high oral bioavailability and a low affinity for CYP450 3A4. The manufacturer recommends caution.

References (1)
  1. (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer